AlphaYou
Overview
Key stats
Fundamentals Sep 10- Open
- $159.90
- 52-wk high
- $165.43
- High
- $160.93
- 52-wk low
- $117.98
- Low
- $159.63
- Prev close
- $163.09
- Mkt cap
- $261.73B
- P/E
- 20.8x
- Volume
- 1.29M
- Fwd P/E
- 16.4x
- Beta
- 0.49
- Div yield
- 2.96%
- P/S
- 4.6x
- P/B
- 7.3x
- Profit margin
- +22.5%
- Op margin
- +34.6%
- ROE
- +30.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 9.5% above what analysts expected.
Earnings per share
$2.20 expected
Reports Oct 27, 2026, in 47 days
EPS expected
$2.20 to $2.26
Revenue expected
4 analysts
Last 30 days
Analysts raising estimates
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $14.36B | $13.33B | $13.52B | $14.42B |
| Cost of what it sold | $3.54B | $3.54B | $3.46B | $3.68B |
| Gross profit | $10.82B | $9.79B | $10.06B | $10.74B |
| What it spent | ||||
| Research and development | $2.94B | $2.84B | $2.74B | $2.76B |
| Sales and admin | $3.31B | $3.44B | $3.14B | $3.24B |
| Other operating costs | $66.0M | — | — | — |
| Total operating expenses | $6.32B | $6.27B | $5.83B | $6.00B |
| What was left | ||||
| Operating profit | $4.50B | $3.52B | $4.24B | $4.74B |
| Interest on debt | $281.0M | $304.0M | $343.0M | $462.3M |
| Profit before tax | $4.20B | $3.22B | $3.84B | $4.27B |
| Tax | $266.0M | $813.9M | $683.0M | $1.01B |
| Net profit | $3.93B | $2.41B | $3.16B | $3.27B |
| EBITDA | $5.84B | $5.07B | $5.41B | $5.94B |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bullish
Tone of tracked coverage
Novartis DM1 Trial Setback Offset by Progress in Neuromuscular Pipeline
NeutralSep 8Novartis India to acquire Pfizer hypertension brand Minipress for ₹1250 crore
Leans bullishSep 8Novartis shares fall after heart drug fails late-stage trial
BearishSep 7Novartis shares down as failed cholesterol drug study increases pipeline pressure
BearishSep 7Novartis Pelacarsen Fails to Cut Cardiovascular Events in Key Phase III Lp(a) Trial
BearishSep 4The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists
BearishSep 4This $3.2 Billion Novartis Bet Is Not a New Drug. It Is a Better Way to Take One
Leans bullishSep 3Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies
NeutralSep 2
Macro
33 macro signals shaping NVS right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results